Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.

Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G.

Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417-3. doi: 10.1016/j.ygyno.2018.11.016. [Epub ahead of print]

PMID:
30446274
2.

Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.

Christodoulou C, Oikonomopoulos G, Koliou GA, Kostopoulos I, Kotoula V, Bobos M, Pentheroudakis G, Lazaridis G, Skondra M, Chrisafi S, Koutras A, Bafaloukos D, Razis E, Papadopoulou K, Papakostas P, Kalofonos HP, Pectasides D, Skarlos P, Kalogeras KT, Fountzilas G.

Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):461-471. doi: 10.21873/cgp.20105.

PMID:
30343280
3.

Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities.

Fountzilas E, Levva S, Mountzios G, Polychronidou G, Maniadakis N, Kotoula V, Fountzilas G.

J Glob Oncol. 2018 Sep;(4):1-12. doi: 10.1200/JGO.18.00115.

4.

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.

Romanidou O, Kotoula V, Fountzilas G.

Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):421-436. doi: 10.21873/cgp.20101. Review.

5.

AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.

Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poulios C, Voutsina A, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilas G.

Clin Colorectal Cancer. 2018 Jun 15. pii: S1533-0028(18)30110-5. doi: 10.1016/j.clcc.2018.06.003. [Epub ahead of print]

PMID:
29980490
6.

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G.

Med Oncol. 2018 May 31;35(7):101. doi: 10.1007/s12032-018-1160-1.

PMID:
29855806
7.

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.

Mehta MA, Schmechtig A, Kotoula V, McColm J, Jackson K, Brittain C, Tauscher-Wisniewski S, Kinon BJ, Morrison PD, Pollak T, Mant T, Williams SCR, Schwarz AJ.

Psychopharmacology (Berl). 2018 Jul;235(7):1875-1886. doi: 10.1007/s00213-018-4877-9. Epub 2018 Mar 21.

PMID:
29564482
8.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

9.

Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.

Papadopoulou K, Murray S, Manousou K, Tikas I, Dervenis C, Sgouros J, Rontogianni D, Lakis S, Bobos M, Poulios C, Pervana S, Lazaridis G, Fountzilas G, Kotoula V.

Am J Cancer Res. 2018 Jan 1;8(1):2-15. eCollection 2018.

10.

Drk-mediated signaling to Rho kinase is required for anesthesia-resistant memory in Drosophila.

Kotoula V, Moressis A, Semelidou O, Skoulakis EMC.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10984-10989. doi: 10.1073/pnas.1704835114. Epub 2017 Sep 25.

11.

Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.

Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Koutras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsa T, Razis E, Kosmidis P, Aravantinos G, Papadimitriou C, Pectasides D, Fountzilas G.

Clin Breast Cancer. 2018 Feb;18(1):53-62.e3. doi: 10.1016/j.clbc.2017.07.004. Epub 2017 Jul 13.

PMID:
28870680
12.

Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.

Fountzilas G, Psyrri A, Giannoulatou E, Tikas I, Manousou K, Rontogianni D, Ciuleanu E, Ciuleanu T, Resiga L, Zaramboukas T, Papadopoulou K, Bobos M, Chrisafi S, Tsolaki E, Markou K, Giotakis E, Koutras A, Psoma E, Kalogera-Fountzila A, Skondra M, Bamia C, Pectasides D, Kotoula V.

Int J Cancer. 2018 Jan 1;142(1):66-80. doi: 10.1002/ijc.31023. Epub 2017 Sep 30.

PMID:
28857155
13.

Protein expression patterns of cell cycle regulators in operable breast cancer.

Zagouri F, Kotoula V, Kouvatseas G, Sotiropoulou M, Koletsa T, Gavressea T, Valavanis C, Trihia H, Bobos M, Lazaridis G, Koutras A, Pentheroudakis G, Skarlos P, Bafaloukos D, Arnogiannaki N, Chrisafi S, Christodoulou C, Papakostas P, Aravantinos G, Kosmidis P, Karanikiotis C, Zografos G, Papadimitriou C, Fountzilas G.

PLoS One. 2017 Aug 10;12(8):e0180489. doi: 10.1371/journal.pone.0180489. eCollection 2017.

14.

Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.

Strati TM, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Lazaridis G, Lakis S, Pentheroudakis G, Pectasides D, Pazarli E, Christodoulou C, Razis E, Pavlakis K, Magkou C, Chrisafi S, Aravantinos G, Bafaloukos D, Papakostas P, Gogas H, Kalogeras KT, Fountzilas G.

Anticancer Res. 2017 May;37(5):2323-2334.

PMID:
28476798
15.

The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.

Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM.

Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017.

16.

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulias K, Karavasilis V, Pentheroudakis G, Balassi E, Zagouri F, Kaklamanos IG, Pectasides D, Razis E, Aravantinos G, Papakostas P, Bafaloukos D, Rallis G, Gogas H, Fountzilas G.

Cancer Genomics Proteomics. 2017 May-Jun;14(3):181-195.

17.

The fate of BRCA1-related germline mutations in triple-negative breast tumors.

Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.

Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.

18.

Intradural extramedullary Ewing's sarcoma: A case report and review of the literature.

Paterakis K, Brotis A, Tasiou A, Kotoula V, Kapsalaki E, Vlychou M.

Neurol Neurochir Pol. 2017 Jan - Feb;51(1):106-110. doi: 10.1016/j.pjnns.2016.11.006. Epub 2016 Nov 30. Review.

PMID:
27939398
19.

Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer.

Pectasides D, Kotoula V, Papaxoinis G, Alexopoulou Z, Dervenis C, Samantas E, Papaparaskeva K, Charalambous E, Gkakou C, Agalianos C, Kalogeras KT, Pentheroudakis G, Fountzilas G.

Anticancer Res. 2016 Dec;36(12):6347-6356.

PMID:
27919956
20.

Disease evolution and heterogeneity in bilateral breast cancer.

Fountzilas E, Kotoula V, Zagouri F, Giannoulatou E, Kouvatseas G, Pentheroudakis G, Koletsa T, Bobos M, Papadopoulou K, Samantas E, Demiri E, Miliaras S, Christodoulou C, Chrisafi S, Razis E, Fostira F, Pectasides D, Zografos G, Fountzilas G.

Am J Cancer Res. 2016 Nov 1;6(11):2611-2630. eCollection 2016.

21.

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.

Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, Nicolaou I, Razis E, Psyrri A, Kosmidis P, Papadimitriou C, Fountzilas G.

PLoS One. 2016 Sep 29;11(9):e0163138. doi: 10.1371/journal.pone.0163138. eCollection 2016.

22.

Towards tumor immunodiagnostics.

Kourea H, Kotoula V.

Ann Transl Med. 2016 Jul;4(14):263. doi: 10.21037/atm.2016.07.07. Review.

23.

Overview of advances in cancer immunotherapy.

Kotoula V, Fountzilas G.

Ann Transl Med. 2016 Jul;4(14):260. doi: 10.21037/atm.2016.07.09. No abstract available.

24.

Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.

Kotoula V, Karavasilis V, Zagouri F, Kouvatseas G, Giannoulatou E, Gogas H, Lakis S, Pentheroudakis G, Bobos M, Papadopoulou K, Tsolaki E, Pectasides D, Lazaridis G, Koutras A, Aravantinos G, Christodoulou C, Papakostas P, Markopoulos C, Zografos G, Papandreou C, Fountzilas G.

Breast Cancer Res Treat. 2016 Jul;158(2):307-21. doi: 10.1007/s10549-016-3883-z. Epub 2016 Jul 1.

PMID:
27369359
25.

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.

Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G.

J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z.

26.

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poulios C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V.

Oncotarget. 2016 May 31;7(22):32731-53. doi: 10.18632/oncotarget.9022.

27.

Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.

Lakis S, Dimoudis S, Kotoula V, Alexopoulou Z, Kostopoulos I, Koletsa T, Bobos M, Timotheadou E, Papaspirou I, Efstratiou I, Aravantinos G, Karavasilis V, Zagouri F, Gogas H, Razis E, Pentheroudakis G, Christodoulou C, Pectasides D, Fountzilas G.

Anticancer Res. 2016 May;36(5):2365-78.

PMID:
27127145
28.

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.

Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A; Jane Carpenter for ABCTC Investigators, Eccles DM, Vachon CM, Couch FJ.

Breast Cancer Res Treat. 2016 May;157(1):117-31. doi: 10.1007/s10549-016-3775-2. Epub 2016 Apr 15.

29.

Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts: Report of a Unique Case With Immunohistochemical and Molecular Studies.

Hatzibougias DI, Fouzas I, Bobos M, Papanikolaou V, Daoudaki M, Kotoula V, Hytiroglou P, Albores-Saavedra J.

Int J Surg Pathol. 2016 Jun;24(4):347-52. doi: 10.1177/1066896915625110. Epub 2016 Jan 13.

PMID:
26762143
30.

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005. Epub 2015 Nov 11.

31.

Expression pattern of the Hedgehog signaling pathway in pituitary adenomas.

Yavropoulou MP, Maladaki A, Topouridou K, Kotoula V, Poulios C, Daskalaki E, Foroglou N, Karkavelas G, Yovos JG.

Neurosci Lett. 2016 Jan 12;611:94-100. doi: 10.1016/j.neulet.2015.10.076. Epub 2015 Nov 24.

PMID:
26620835
32.

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.

Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H, Galani E, Efstratiou I, Zaramboukas T, Koutras A, Aravantinos G, Samantas E, Psyrri A, Kourea H, Bobos M, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G.

Oncotarget. 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231.

33.

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.

Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G.

PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015.

34.

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A.

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543. Epub 2015 Sep 25.

35.

Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe.

Stone J, Kotoula V, Dietrich C, De Simoni S, Krystal JH, Mehta MA.

J Psychopharmacol. 2015 Sep;29(9):1025-8. doi: 10.1177/0269881115592337. Epub 2015 Jul 6.

PMID:
26152321
36.

Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA.

Kotoula V, Lyberopoulou A, Papadopoulou K, Charalambous E, Alexopoulou Z, Gakou C, Lakis S, Tsolaki E, Lilakos K, Fountzilas G.

PLoS One. 2015 Jun 3;10(6):e0128818. doi: 10.1371/journal.pone.0128818. eCollection 2015.

37.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

38.

Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.

Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G.

PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015.

39.

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.

BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.

40.

Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.

Kourea HP, Kotoula V, Koutras A, Alexopoulou Z, Papaspirou I, Skarlos DV, Efstratiou I, Bobos M, Zagouri F, Papakostas P, Pectasides D, Chrisafi S, Varthalitis I, Aravantinos G, Kosmidis P, Bafaloukos D, Scopa CD, Fountzilas G.

Histol Histopathol. 2015 Sep;30(9):1129-41. doi: 10.14670/HH-11-612. Epub 2015 Mar 25.

PMID:
25807307
41.

Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.

Koutras A, Kotoula V, Fountzilas G.

Pharmacogenomics. 2015 Jan;16(1):79-94. doi: 10.2217/pgs.14.148. Review.

PMID:
25560472
42.

Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer.

Krikelis D, Kotoula V, Bobos M, Fountzilas E, Markou K, Karasmanis I, Angouridakis N, Vlachtsis K, Kalogeras KT, Nikolaou A, Fountzilas G.

Anticancer Res. 2014 Nov;34(11):6495-503.

PMID:
25368251
43.

Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.

Karavasilis V, Kosmidis P, Syrigos KN, Mavropoulou P, Dimopoulos MA, Kotoula V, Pectasides D, Boukovinas I, Klouvas G, Kalogera-Fountzila A, Papandreou CN, Fountzilas G, Briasoulis E.

Anticancer Res. 2014 Oct;34(10):5649-55.

PMID:
25275069
44.

Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.

Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C, Xanthakis I, Kalogeras KT, Basdanis G, Pentheroudakis G, Kotoula V, Fountzilas G.

Anticancer Res. 2014 Sep;34(9):4949-62.

PMID:
25202077
45.

Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).

Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, Lazaridis G, Papadopoulou K, Efstratiou I, Michail-Strantzia C, Debelenko LV, Kosmidis P, Fountzilas G.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.

PMID:
25153496
46.

Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.

Kotoula V, Bobos M, Alexopoulou Z, Papadimitriou C, Papadopoulou K, Charalambous E, Tsolaki E, Xepapadakis G, Nicolaou I, Papaspirou I, Aravantinos G, Christodoulou C, Efstratiou I, Gogas H, Fountzilas G.

PLoS One. 2014 Aug 6;9(8):e103707. doi: 10.1371/journal.pone.0103707. eCollection 2014.

47.

p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.

Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G.

Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2. Epub 2014 Aug 8.

PMID:
25098276
48.

Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.

Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N.

Clin Exp Metastasis. 2014 Oct;31(7):761-9. doi: 10.1007/s10585-014-9666-1. Epub 2014 Jul 5.

PMID:
24997156
49.

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.

Koletsa T, Stavridi F, Bobos M, Kostopoulos I, Kotoula V, Eleftheraki AG, Konstantopoulou I, Papadimitriou C, Batistatou A, Gogas H, Koutras A, Skarlos DV, Pentheroudakis G, Efstratiou I, Pectasides D, Fountzilas G.

BMC Clin Pathol. 2014 Jun 23;14:28. doi: 10.1186/1472-6890-14-28. eCollection 2014.

50.

In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014.

Supplemental Content

Loading ...
Support Center